Appointments support ongoing Phase 2
COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial
of VE303 and planning for commercial stage activity
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company dedicated to
changing the lives of patients with devastating diseases, noted
that its Founded Entity, Vedanta Biosciences, a clinical-stage
biopharmaceutical company developing medicines for the treatment of
gastrointestinal diseases, today announced three appointments to
its leadership team. Christof Marré, a seasoned biopharma marketing
leader, joins the company as Senior Vice President and Head of
Commercial. In addition, Steven Shiff, M.D., a pharmaceutical
executive and physician specializing in gastroenterology, has been
appointed as SVP, Clinical Research; and Jack Kyte has been
promoted to SVP, Human Resources.
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Expands Leadership Team
and Appoints Head of Commercial
Appointments support ongoing Phase 2
COLLECTiVE202 trial of VE202, pivotal Phase 3 RESTORATiVE303 trial
of VE303 and planning for commercial stage activity
CAMBRIDGE, MA, July 23, 2024 – Vedanta Biosciences, a
clinical-stage biopharmaceutical company developing medicines for
the treatment of gastrointestinal diseases, today announced three
appointments to its leadership team. Christof Marré, a seasoned
biopharma marketing leader, joins the company as Senior Vice
President and Head of Commercial. In addition, Steven Shiff, M.D.,
a pharmaceutical executive and physician specializing in
gastroenterology, has been appointed as SVP, Clinical Research; and
Jack Kyte has been promoted to SVP, Human Resources.
“I am delighted to welcome Christof and Steve to the team,” said
Bernat Olle, Ph.D., Co-Founder and Chief Executive Officer of
Vedanta Biosciences. “The expertise that Christof, Steve, and Jack
bring are vital to our next phase of growth as we execute our
ongoing pivotal Phase 3 RESTORATiVE303 trial of VE303 for C.
difficile infection and Phase 2 COLLECTiVE202 trial of VE202 for
ulcerative colitis, and establish our commercial function.”
Christof Marré brings almost three decades of experience as a
biopharma marketing leader and strategist, and most recently served
as VP of Marketing & Pipeline Planning at Alpine Immune
Sciences, recently acquired by Vertex Pharmaceuticals. At Alpine,
he established the company’s Commercial function, including
building out capabilities in market research, competitive
intelligence, healthcare practitioner marketing & patient
advocacy, and driving indication prioritization and valuation
within the company’s Immunology portfolio. Earlier in his career,
Mr. Marré was involved with multiple successful product launches at
both established and emerging biopharma companies. He holds a
Master of Science degree in Economics from The London School of
Economics and Political Science (LSE).
Steven Shiff, M.D., is a gastroenterologist and clinical
executive with over 20 years of experience in research and industry
R&D. Dr. Shiff was most recently SVP and Head of Clinical
Development at Intercept Pharmaceuticals, where he oversaw design
and implementation of the company’s global clinical development
strategy focused on rare and serious liver diseases, including
supporting an NDA filing. Previously, he served as VP, Clinical
Development, and GI Therapeutic Area Head at Allergan for 14 years,
in which capacity he led global clinical development of the
company’s GI pipeline and marketed GI product portfolio. Dr. Shiff
spent the first 13 years of his career as a practicing physician
and professor, initially at The Rockefeller University and later at
Rutgers-Robert Wood Johnson Medical School.
Jack Kyte has served as Vice President and Head of Human
Resources at Vedanta since 2020, following more than a decade of
multi-industry HR experience. Mr. Kyte is responsible for
developing and executing Vedanta’s people strategy in alignment
with the organization’s current and anticipated future needs and
overseeing its human resources function both internally and with
external partners.
About Vedanta Biosciences
Vedanta Biosciences is a clinical-stage biopharmaceutical
company developing medicines for the treatment of gastrointestinal
diseases. The company’s lead assets are potential first-in-class
oral therapies – VE303, in a Phase 3 registrational trial for
prevention of recurrent C. difficile infection, and VE202, in a
Phase 2 trial for treatment of ulcerative colitis. Vedanta’s
pipeline has been built using the company’s industry-leading
product engine for the development of therapies based on defined
consortia of bacteria grown from pure clonal cell banks. The
product engine, supported by broad foundational intellectual
property, includes one of the largest libraries of bacteria
isolated from the human microbiome, vast clinical datasets,
proprietary capabilities in consortium design, and end-to-end CGMP
manufacturing capabilities at commercial launch scale.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to giving life to new classes of medicine to change the lives of
patients with devastating diseases. The Company has created a broad
and deep pipeline through its experienced research and development
team and its extensive network of scientists, clinicians and
industry leaders that is being advanced both internally and through
its Founded Entities. PureTech's R&D engine has resulted in the
development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and
European marketing authorization and a third (KarXT) that has been
filed for FDA approval. A number of these programs are being
advanced by PureTech or its Founded Entities in various indications
and stages of clinical development, including registration enabling
studies. All of the underlying programs and platforms that resulted
in this pipeline of therapeutic candidates were initially
identified or discovered and then advanced by the PureTech team
through key validation points.
For more information, visit www.puretechhealth.com or connect
with us on X (formerly Twitter) @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this press release that do not relate to matters of historical
fact should be considered forward-looking statements, including
without limitation those related to the VE303 and VE202 development
programs, development plans and potential benefits to patients and
our future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks, uncertainties and other
important factors that could cause actual results, performance and
achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other
important factors described under the caption "Risk Factors" in our
Annual Report on Form 20-F for the year ended December 31, 2023,
filed with the SEC and in our other regulatory filings. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the Company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, we
disclaim any obligation to update or revise these forward-looking
statements, whether as a result of new information, future events
or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240723091412/en/
PureTech Public Relations
publicrelations@puretechhealth.com Investor Relations
IR@puretechhealth.com
UK/EU Media Ben Atwell, Rob Winder +44 (0) 20 3727 1000
puretech@fticonsulting.com
US Media Nichole Bobbyn +1 774 278 8273
nichole@tenbridgecommunications.com
Grafico Azioni PureTech Health (NASDAQ:PRTC)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni PureTech Health (NASDAQ:PRTC)
Storico
Da Dic 2023 a Dic 2024
